Companies /Healthcare

Aclaris Therapeutics Inc

NASDAQ: ACRS Biotechnology
$3.39
▼ $0.22 (−6.10%) today
Markets open · 2:37pm ET

ACRS at a Glance

Valuation
Market cap
$621.8M
Profitability
Revenue (TTM)
$6.4M
EPS (TTM)
$-0.59
Price
52-week range
$2 – $7
Street target
$10.36

Headquartered in Wayne, PA Fiscal year ends December NASDAQ: ACRS aclaristx.com

About Aclaris Therapeutics

Aclaris Therapeutics is a clinical-stage biopharmaceutical company developing novel product candidates for immuno-inflammatory diseases where patients lack satisfactory treatment options.

Its pipeline spans two franchises:
- **Biologics (antibody) franchise:**
- ATI-052, a bispecific anti-TSLP/IL-4Rα antibody that reported positive Phase 1b results in atopic dermatitis and asthma. It is being prioritized for Phase 2b development in eosinophilic esophagitis.
- Bosakitug (ATI-045), an anti-TSLP monoclonal antibody in the Phase 2 ADMIRATION trial for atopic dermatitis.
- **Kinase inhibitor (ITK) franchise:**
- Modzatinib (ATI-2138), an oral ITK/JAK3 inhibitor heading into a Phase 2b trial in lichen planus.
- ATI-9494, a dual ITK/TXK inhibitor nearing an IND filing.

The company generates modest revenue from two sources:
- Licensing, including a license agreement with Sun Pharma that carries sales milestones.
- Contract research services.

It also records non-cash royalty income. Updated

Latest Activity

ACRSAclaris Therapeutics
Q3 2026
EPS
-$0.12
est -$0.16+25.8%
Revenue
$1M
est $1M+20.9%

A $50 million October raise just pushed Aclaris's cash runway through the first half of 2029, funding Phase 2b trials of ATI-052 and modzatinib. Top-line ADMIRATION results for bosakitug in atopic dermatitis land this quarter, making the next few weeks the real catalyst.

Quarterly EPS — reported vs estimate

ACRS Coverage

Frequently Asked Questions

What does Aclaris Therapeutics do?

Aclaris Therapeutics is a clinical-stage biopharmaceutical company developing novel product candidates for immuno-inflammatory diseases where patients lack satisfactory treatment options.

What is the ACRS stock price target?

The Wall Street consensus 12-month price target for ACRS is $10.36.